Table 1.
Groups | MDA (μmol/mg protein) | % inhibition of O2- | GPx activity (Unit/g protein) | MAO-A activity (μmol/min.g tissue) | MAO-B activity (μmol/min.g tissue) | |||||
---|---|---|---|---|---|---|---|---|---|---|
cortex | striatum | cortex | striatum | cortex | striatum | cortex | striatum | cortex | striatum | |
Control | 2.22 ± 0.26 | 1.53 ± 0.56 | 16.48 ± 2.14 | 19.87 ± 1.99 | 18.45 ± 1.70 | 20.87 ± 1.68 | 3.00 ± 1.01 | 2.73 ± 1.05 | 5.01 ± 1.01 | 4.73 ± 1.05 |
Vehicle+MPTP | 6.34 ± 0.41a | 5.96 ± 0.22a | 5.16 ± 1.46a | 8.32 ± 1.10a | 5.09 ± 2.27a | 6.54 ± 2.04a | 9.02 ± 1.00a | 10.13 ± 1.18a | 15.00 ± 1.04a | 17.13 ± 1.18a |
Tidomet plus 25 + MPTP | 2.81 ± 0.48b | 1.70 ± 0.13b | 13.08 ± 1.95b | 11.87 ± 2.03b | 15.92 ± 0.81b | 13.41 ± 1.61b | 5.46 ± 0.67b | 6.16 ± 1.25a | 10.46 ± 0.67b | 8.16 ± 1.25b |
AGME 125 + MPTP | 2.93 ± 0.41 | 4.77 ± 0.15 | 10.85 ± 1.55 | 9.98 ± 2.55 | 6.19 ± 1.81 | 7.83 ± 0.93 | 8.51 ± 1.19 | 9.56 ± 1.34 | 11.51 ± 1.19 | 10.56 ± 1.34 |
AGME 250 + MPTP | 2.12 ± 0.43b | 3.75 ± 0.12b | 12.05 ± 1.99b | 14.04 ± 2.26b | 10.55 ± 1.18b | 12.37 ± 1.15b | 5.86 ± 0.68b | 6.70 ± 0.57 b | 10.86 ± 0.68b | 8.70 ± 0.57b |
AGME 375 + MPTP | 2.01 ± 0.35b | 0.17 ± 0.19 b | 15.75 ± 1.13b | 18.14 ± 1.26b,c | 16.54 ± 1.16b | 18.71 ± 1.26b,c | 4.21 ± 0.52b | 3.42 ± 0.72b,c | 6.21 ± 0.53b,c | 4.42 ± 0.72b,c |
Data were represented as mean ± S.D. of three replicates, n = 8 each, a vs. control group, p < 0.01; b vs. vehicle+MPTP-treated group, p < 0.05; c vs.Tidomet plus 25 + MPTP-treated group, p < 0.05